Related Experiment Videos
Immune deficiency presenting as mycobacterial infection
1Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, 11N103, 10 Center Dr., MSC 1886 Bethesda, MD 20892-1886, USA.
Clinical Reviews in Allergy & Immunology
|March 28, 2001
Summary
Genetic defects reveal Interferon-gamma (IFN-gamma) is critical for controlling non-tuberculous mycobacteria (NTM) and BCG infections. Further research is needed to identify other cytokines for improved antimycobacterial therapies.
Area of Science:
- Immunology
- Genetics
- Infectious Diseases
Background:
- Genetic defects predisposing to non-tuberculous mycobacteria (NTM) and Bacillus Calmette-Guérin (BCG) infections are primarily linked to Interferon-gamma (IFN-gamma) pathways.
- This suggests IFN-gamma plays a crucial role in controlling mycobacterial infections.
Purpose of the Study:
- To understand the critical mechanisms underlying mycobacterial infection control.
- To identify potential therapeutic targets beyond IFN-gamma for treating mycobacterial and other intracellular infections.
Main Methods:
- Analysis of naturally occurring genetic defects associated with NTM and BCG susceptibility.
- Review of existing literature on cytokine involvement in host defense against intracellular pathogens.
Main Results:
- Genetic studies consistently implicate IFN-gamma pathways in susceptibility to NTM and BCG.
- IFN-gamma appears to be a key cytokine in controlling mycobacteria, but its precise mechanism of action remains unclear.
Conclusions:
- While IFN-gamma is critical, other cytokines or chemokines may be more effective therapeutic agents for antimycobacterial mechanisms.
- Future research should focus on dissecting these pathways to identify proximal factors for novel treatment strategies against mycobacterial and intracellular infections.